Appointment of Interim Chief Executive Officer
Microba Life Sciences Ltd
Key points
- Dr. Luke Reid on medical leave
- Geoffrey Cockerill appointed as Interim CEO
- Experienced executive with leadership roles at Diageo, Lion, and Subway
- Initial term of six months, extendable by mutual agreement
- Daily fee of $2,100 (excluding GST), five days per week
Full summary
Microba Life Sciences Ltd (ASX: MAP) has announced that its Chief Executive Officer, Dr. Luke Reid, is on medical leave. To ensure leadership continuity, the Board has appointed Mr. Geoffrey Cockerill as Interim Chief Executive Officer, effective 29 September 2026. Mr. Cockerill brings over 30 years of leadership experience from roles at Diageo Australia, Lion, and Subway Systems, where he held senior positions in Australia, New Zealand, and South-East Asia. He has also served as CEO of Vitura Health Limited and ATP Science, leading transformation and growth initiatives. His engagement as Interim CEO is for an initial term of six months, extendable by mutual agreement, with a daily fee of $2,100 (excluding GST), inclusive of superannuation, on the basis of five days per week.